Spleen tyrosine kinase inhibitor effect on diffuse large B-cell lymphoma cell lines: time course
Summary:
Analysis of the DHL4 and DHL6 diffuse large B-cell lymphoma (DLBCL) cell lines following treatment with R406, a spleen tyrosine kinase (SYK) inhibitor. SYK is a key component of BCR signaling which is a critical pathway in DLBCL. Results provide insight into the role of SYK in DLBCL pathogenesis.
GPL3921:
[HT_HG-U133A] Affymetrix HT Human Genome U133A Array
Citation:
Chen L, Monti S, Juszczynski P, Ouyang J et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013 Jun 10;23(6):826-38. PMID: 23764004
